search icon
crdl-img

Cardiol Therapeutics Inc Class A Share Price

CRDL
NAQ
$1.015
+$0.05
(5.2%)
1D
Industry: Biotechnology Sector: Health Care

Cardiol Therapeutics Inc Class A Analyst Forecast

Cardiol Therapeutics Inc Class A Share Price Chart

Cardiol Therapeutics Inc Class A Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$107.04M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
452.25K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.69
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.77 L
$1.59 H
$1.015

About Cardiol Therapeutics Inc Class A, Common Stock

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. more

Industry: BiotechnologySector: Health Care

Cardiol Therapeutics Inc Class A Stock Returns

Time FrameCRDLSectorS&P500
1-Week Return-3.93%-1.52%0.41%
1-Month Return-3.37%0.12%1.81%
3-Month Return-12.26%7.78%1.82%
6-Month Return-24.95%17.05%10.26%
1-Year Return-27.77%5.6%16.37%
3-Year Return38.03%16.99%67.04%
5-Year Return-61.34%34.45%82.38%
10-Year Return-74.33%137.3%266.85%

Cardiol Therapeutics Inc Class A Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue78.76K62.27K---[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.06,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue180.17K174.26K162.23K187.38K-[{"date":"2020-12-31","value":96.15,"profit":true},{"date":"2021-12-31","value":93,"profit":true},{"date":"2022-12-31","value":86.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(180.17K)(112.00K)(162.23K)(187.38K)-[{"date":"2020-12-31","value":-18017100,"profit":false},{"date":"2021-12-31","value":-11199700,"profit":false},{"date":"2022-12-31","value":-16222600,"profit":false},{"date":"2023-12-31","value":-18738300,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(228.76%)(179.87%)---[{"date":"2020-12-31","value":-228.76,"profit":false},{"date":"2021-12-31","value":-179.87,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses16.06M30.46M30.33M22.29M40.28M[{"date":"2020-12-31","value":39.88,"profit":true},{"date":"2021-12-31","value":75.62,"profit":true},{"date":"2022-12-31","value":75.31,"profit":true},{"date":"2023-12-31","value":55.33,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(16.24M)(30.57M)(30.49M)(22.47M)(40.28M)[{"date":"2020-12-31","value":-1624055000,"profit":false},{"date":"2021-12-31","value":-3056839100,"profit":false},{"date":"2022-12-31","value":-3049347700,"profit":false},{"date":"2023-12-31","value":-2247316200,"profit":false},{"date":"2024-12-31","value":-4027665100,"profit":false}]
Total Non-Operating Income/Expense115.46K5.66M8.91M3.43M4.79M[{"date":"2020-12-31","value":1.3,"profit":true},{"date":"2021-12-31","value":63.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.43,"profit":true},{"date":"2024-12-31","value":53.77,"profit":true}]
Pre-Tax Income(16.20M)(25.01M)(22.82M)(21.22M)(36.68M)[{"date":"2020-12-31","value":-1620167500,"profit":false},{"date":"2021-12-31","value":-2501319500,"profit":false},{"date":"2022-12-31","value":-2281753800,"profit":false},{"date":"2023-12-31","value":-2122279600,"profit":false},{"date":"2024-12-31","value":-3667729900,"profit":false}]
Income Taxes7.40K(6.91M)(10.24M)5.00-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-93462.12,"profit":false},{"date":"2022-12-31","value":-138426.44,"profit":false},{"date":"2023-12-31","value":0.07,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(16.21M)(18.10M)(12.58M)(21.22M)-[{"date":"2020-12-31","value":-1620907300,"profit":false},{"date":"2021-12-31","value":-1809886700,"profit":false},{"date":"2022-12-31","value":-1257675000,"profit":false},{"date":"2023-12-31","value":-2122280100,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(20.64M)(31.64M)(30.93M)(28.01M)(36.68M)[{"date":"2020-12-31","value":-2064093500,"profit":false},{"date":"2021-12-31","value":-3163824400,"profit":false},{"date":"2022-12-31","value":-3093064700,"profit":false},{"date":"2023-12-31","value":-2800629300,"profit":false},{"date":"2024-12-31","value":-3667729900,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(16.20M)(25.01M)(22.82M)(21.22M)(36.68M)[{"date":"2020-12-31","value":-1620167500,"profit":false},{"date":"2021-12-31","value":-2501319500,"profit":false},{"date":"2022-12-31","value":-2281753800,"profit":false},{"date":"2023-12-31","value":-2122279600,"profit":false},{"date":"2024-12-31","value":-3667729900,"profit":false}]
EPS (Diluted)(0.46)(0.71)(0.49)(0.41)(0.49)[{"date":"2020-12-31","value":-46.21,"profit":false},{"date":"2021-12-31","value":-70.97,"profit":false},{"date":"2022-12-31","value":-49,"profit":false},{"date":"2023-12-31","value":-41,"profit":false},{"date":"2024-12-31","value":-49,"profit":false}]

Cardiol Therapeutics Inc Class A Ratios

Cardiol Therapeutics Inc Class A Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CRDL
Cash Ratio 3.53
Current Ratio 3.89

Cardiol Therapeutics Inc Class A Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRDL
ROA (LTM) -148.83%
ROE (LTM) -347.98%

Cardiol Therapeutics Inc Class A Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRDL
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Cardiol Therapeutics Inc Class A Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRDL
Trailing PE NM
Forward PE NM
P/S (TTM) 1069.35
P/B 15.53
Price/FCF NM
EV/R 178.81
EV/Ebitda 0.30

FAQs

What is Cardiol Therapeutics Inc Class A share price today?

Cardiol Therapeutics Inc Class A (CRDL) share price today is $1.015

Can Indians buy Cardiol Therapeutics Inc Class A shares?

Yes, Indians can buy shares of Cardiol Therapeutics Inc Class A (CRDL) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRDL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cardiol Therapeutics Inc Class A be purchased?

Yes, you can purchase fractional shares of Cardiol Therapeutics Inc Class A (CRDL) via the Vested app. You can start investing in Cardiol Therapeutics Inc Class A (CRDL) with a minimum investment of $1.

How to invest in Cardiol Therapeutics Inc Class A shares from India?

You can invest in shares of Cardiol Therapeutics Inc Class A (CRDL) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRDL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cardiol Therapeutics Inc Class A shares
What is Cardiol Therapeutics Inc Class A 52-week high and low stock price?

The 52-week high price of Cardiol Therapeutics Inc Class A (CRDL) is $1.59. The 52-week low price of Cardiol Therapeutics Inc Class A (CRDL) is $0.77.

What is Cardiol Therapeutics Inc Class A price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cardiol Therapeutics Inc Class A (CRDL) is

What is Cardiol Therapeutics Inc Class A price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cardiol Therapeutics Inc Class A (CRDL) is 15.53

What is Cardiol Therapeutics Inc Class A dividend yield?

The dividend yield of Cardiol Therapeutics Inc Class A (CRDL) is 0.00%

What is the Market Cap of Cardiol Therapeutics Inc Class A?

The market capitalization of Cardiol Therapeutics Inc Class A (CRDL) is $107.04M

What is Cardiol Therapeutics Inc Class A's stock symbol?

The stock symbol (or ticker) of Cardiol Therapeutics Inc Class A is CRDL

How Can Investors Use Cardiol Therapeutics Inc Class A Share Price Data for Long-Term Investment Decisions?

Consider the share price of Cardiol Therapeutics Inc Class A as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cardiol Therapeutics Inc Class A has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Cardiol Therapeutics Inc Class A shares for Indian investors?

When investing in Cardiol Therapeutics Inc Class A shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cardiol Therapeutics Inc Class A stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Cardiol Therapeutics Inc Class A share price with other stocks in the same sector?

Rather than merely checking the share price of Cardiol Therapeutics Inc Class A and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cardiol Therapeutics Inc Class A stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top